In the case of metabolic disorders, there is either an alteration in acid ceramidase activity or a change in the expression level of ASAH1 in Alzheimer’s disease [26], cancer [27,28,29], and type 2 diabetes [30]. Here, ASAH1 is linked to Alzheimer disease.